WallStSmart

Cardinal Health Inc (CAH)vsSynopsys Inc (SNPS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cardinal Health Inc generates 3031% more annual revenue ($250.74B vs $8.01B). SNPS leads profitability with a 13.8% profit margin vs 0.6%. CAH appears more attractively valued with a PEG of 1.25. SNPS earns a higher WallStSmart Score of 47/100 (D+).

CAH

Hold

47

out of 100

Grade: D+

Growth: 4.7Profit: 4.5Value: 7.3Quality: 5.8
Piotroski: 4/9Altman Z: 4.30

SNPS

Hold

47

out of 100

Grade: D+

Growth: 6.7Profit: 5.0Value: 3.0Quality: 4.5
Piotroski: 1/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CAHUndervalued (+73.9%)

Margin of Safety

+73.9%

Fair Value

$859.62

Current Price

$183.65

$675.97 discount

UndervaluedFair: $859.62Overvalued

Intrinsic value data unavailable for SNPS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CAH2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.3010/10

Safe zone — low bankruptcy risk

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

SNPS2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
65.5%10/10

Revenue surging 65.5% year-over-year

Market CapQuality
$98.94B9/10

Large-cap with strong market position

Areas to Watch

CAH4 concerns · Avg: 3.3/10
P/E RatioValuation
28.2x4/10

Moderate valuation

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.6%3/10

0.6% margin — thin

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

SNPS4 concerns · Avg: 2.5/10
Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

PEG RatioValuation
3.312/10

Expensive relative to growth rate

P/E RatioValuation
79.2x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : CAH

The strongest argument for CAH centers on Altman Z-Score, Free Cash Flow. Revenue growth of 11.0% demonstrates continued momentum. PEG of 1.25 suggests the stock is reasonably priced for its growth.

Bull Case : SNPS

The strongest argument for SNPS centers on Revenue Growth, Market Cap. Revenue growth of 65.5% demonstrates continued momentum.

Bear Case : CAH

The primary concerns for CAH are P/E Ratio, Return on Equity, Profit Margin. Thin 0.6% margins leave little buffer for downturns.

Bear Case : SNPS

The primary concerns for SNPS are Return on Equity, Piotroski F-Score, PEG Ratio. A P/E of 79.2x leaves little room for execution misses.

Key Dynamics to Monitor

CAH profiles as a value stock while SNPS is a growth play — different risk/reward profiles.

SNPS carries more volatility with a beta of 1.25 — expect wider price swings.

SNPS is growing revenue faster at 65.5% — sustainability is the question.

CAH generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

CAH scores higher overall (47/100 vs 47/100) and 11.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardinal Health Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cardinal Health, Inc. is an American multinational health care services company.

Visit Website →

Synopsys Inc

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Synopsys is an American electronic design automation company that focuses on silicon design and verification, silicon intellectual property and software security and quality. Products include logic synthesis, behavioral synthesis, place and route, static timing analysis, formal verification, hardware description language (SystemC, SystemVerilog/Verilog, VHDL) simulators, and transistor-level circuit simulation.

Visit Website →

Want to dig deeper into these stocks?